Arcus Biosciences Announces Participation at Upcoming Investor Conference
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer
immunotherapies, today announced that Terry Rosen, Ph.D., Chief Executive Officer, will participate in a fireside chat at the
Goldman Sachs 39th Annual Global Healthcare Conference on Tuesday, June 12, 2018 at 8:40 am PT at the Terranea Resort,
in Rancho Palos Verdes, CA.
Individuals may access the live audio webcast by visiting the “Events & Presentations” section of the Company’s website at
https://investors.arcusbio.com/investors/investor-relations/default.aspx. A replay of the webcast will be
available for 30 days following the live event.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer
immunotherapies. Arcus has several programs targeting important immuno-oncology pathways, including a dual adenosine receptor
antagonist and an anti-PD-1 antibody, both of which are in Phase 1 trials, as well as a small molecule inhibitor of CD73 and an
anti-TIGIT antibody, which are in IND-enabling studies. Arcus has extensive in-house expertise in medicinal chemistry,
immunology, biochemistry, pharmacology, and structural biology. For more information about Arcus Biosciences, please visit www.arcusbio.com.
Arcus Biosciences, Inc.
Jennifer Jarrett, 510-694-6261
jjarrett@arcusbio.com
or
Nicole Arndt, 510-284-4728
narndt@arcusbio.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20180529006103/en/